BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: MTNB) announces that on January 6, 2025, it received a ...

Renaissance expects 2025 will be a better year for IPOs. “While some may be skeptical that a pickup is once again ‘right ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Immix Biopharma (IMMX) announced completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an ...

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

After hours: January 6 at 6:44:57 PM EST Loading Chart for IMMX ...

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in developme ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.